MURAGAKI Yoshihiro    Department   School of Medicine(Tokyo Women's Medical University Hospital), School of Medicine    Position   Visiting Professor
Article types	Case report
Language	English
Peer review	Peer reviewed
Title	Epidermal growth factor receptor (EGFR) amplification rates observed in screening patients for randomized trials in glioblastoma
Journal	Formal name：Journal of neuro-oncology Abbreviation：J Neurooncol ISSN code：0167594X/15737373
Domestic / Foregin	Foregin
Volume, Issue, Page	144(1),pp.205-210
Author and coauthor	LASSMAN Andrew B†., ALDAPE Kenneth D. , ANSELL Peter J. , BAIN Earle , CURRAN Walter J., EOIL Marica , FRENCH Pim J. , KINOSHITA Manabu , LOOMAN Jim , MRHTA Minesh, MURAGAKI Yoshihiro, NARITA Yoshitaka, OCAMPO Christopher , LISA Roberts-Rapp, SONG Minghao , VOGELBAUM Michael A., WALENKAMP Annemiek M. E., WANG Tony J. C. , ZHANG Peixin, van den BENT Martin J.
Publication date	2019/08
Summary	Purpose Epidermal growth factor receptor (EGFR) amplification has been reported to occur in ~ 50% of glioblastomas (GBMs). We are conducting several global studies that require central testing for EGFR amplification during screening, representing an opportunity to confirm the frequency of amplification in GBM in a large cohort and to evaluate whether EGFR amplification differs by region of the world. Methods EGFR amplification was measured by fluorescence in situ hybridization during screening for therapeutic trials of an EGFR antibody–drug conjugate: two Phase 2/3 global trials (INTELLANCE-1, INTELLANCE-2), and a Japanese Phase 1/2 trial (INTELLANCE-J). We evaluated the proportion of tumor tissue samples harboring EGFR amplification among those tested and differences in amplification frequency by geography. Results EGFR was amplified in 54% of 3150 informative cases screened for INTELLANCE-1 and -2, consistent with historic controls, but was significantly lower in patients from Asia versus the rest of the world (35% vs. 56%, P < 0.0030). The independent INTELLANCE-J trial validated this finding (33% amplified of 153 informative cases). Conclusions EGFR amplification occurs less frequently in patients from Asia than elsewhere. Further study is required to understand biological differences to optimize treatment in glioblastoma.
DOI	10.1007/s11060-019-03222-y
PMID	31273577